Literature DB >> 11096581

Severe Ulcerative Colitis.

.   

Abstract

Patients with severe ulcerative colitis should be hospitalized and treated with intravenous corticosteroids for 7 to 10 days. Patients who fail to respond may be offered colectomy or rescue therapy with intravenous cyclosporine. Risks of cyclosporine therapy, including a 1% to 2% risk of death from opportunistic infection and a 50% failure rate after 6 months of follow-up, should be discussed with the patient. Because of the high rate of relapse, patients who elect to be treated with cyclosporine should receive overlapping therapy with prednisone, cyclosporine and azathioprine or 6-mercaptopurine. Azathioprine or 6-mercaptopurine should then be continued long-term for maintenance of remission.

Entities:  

Year:  1999        PMID: 11096581     DOI: 10.1007/s11938-999-0038-x

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  3 in total

Review 1.  The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games.

Authors:  Thomas Hehlgans; Klaus Pfeffer
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

2.  Predictors of disease severity in ulcerative colitis patients from Southwestern Ontario.

Authors:  Lee S Roth; Nilesh Chande; Terry Ponich; Maya L Roth; James Gregor
Journal:  World J Gastroenterol       Date:  2010-01-14       Impact factor: 5.742

Review 3.  Review and clinical perspectives for the use of infliximab in ulcerative colitis.

Authors:  R Panaccione; R N Fedorak; G Aumais; Edmond-Jean Bernard; C N Bernstein; A Bitton; K Croitoru; L A Dieleman; R Enns; B G Feagan; D Franchimont; G R Greenberg; Anne-Marie Griffiths; J K Marshall; P Pare; S Patel; R Penner; C Render; E Seidman; A Hillary Steinhart
Journal:  Can J Gastroenterol       Date:  2008-03       Impact factor: 3.522

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.